Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7033 - 7040 of 12091 results
Blue Cross Exec Tests HIPAA By Describing $12M Patient
June 1, 2017| News
FTC’s First Test of Supreme Court’s North Carolina Dental Precedent in New Case against Real Estate Appraisal Board
June 1, 2017| Alert| Viewpoint
Getting Ready for Change in the EB-5 Ecosystem
June 1, 2017| Blog| Viewpoint
Supreme Court Overrules and Rewrites 25 Years of Federal Circuit Law on Patent Exhaustion
May 31, 2017| Blog| Viewpoint
FDA Commissioner Hints at Drug Pricing-Related Initiatives
May 31, 2017| Blog| Viewpoint
The DTSA and Inevitable Disclosure
May 30, 2017| Blog| Viewpoint
Mintz’s Employment Matters Blog Analyzes Efforts to Shore up MassHealth
May 30, 2017| Blog| Viewpoint
How Bad Things Happen to Good Companies—And What You Can Do About It
May 30, 2017| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|